Food and Drug Administration
Briefing
Information
FDA
The committee will discuss class labeling of antihypertensive drugs
based on the proximity of their data to outcome trials.
Disclaimer
Portions of this document have been determined to be
exempt from disclosure under the Freedom of Information Act (the FOIA) (5
U.S.C. §552)
These redacted portions will appear as
white space on the screen or on the printed page.